AI Article Synopsis
- Hypochondroplasia is a genetic condition leading to short stature with minor symptoms, and this study investigates the long-term effects of growth hormone (GH) therapy in affected individuals who did not respond well to initial GH tests.
- Six patients, averaging 7.42 years old and with a significant height deficit, underwent GH treatment at a dose of 0.2 mg/kg/week for about 4.45 years.
- While the study observed initial growth in the first year of therapy, the overall height gains were not enough for patients to reach an adequate final height.
Article Abstract
Hypochondroplasia is a cause of disproportionate short stature and characterized by minor clinical manifestations. The aim of this study was to evaluate the efficacy of long-term growth hormone (GH) therapy in hypochondroplastic cases with inadequate response to GH stimulation tests. In this study, six patients who had a height standard deviation score of -3.43 before the treatment and a mean age of 7.42 years and who had received GH treatment at a dose of 0.2 mg/kg/week for a mean period of 4.45 years were evaluated. A good response was found in the first year of treatment, but this increase was not found to be sufficient for the patients to achieve an adequate final height.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280321 | PMC |
| http://dx.doi.org/10.4274/jcrpe.0043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!